ArticleDiagnostic and interventional radiology (Ankara, Turkey)2025
Machine learning models for discriminating clinically significant from clinically insignificant prostate cancer using bi-parametric magnetic resonance imaging
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting intermediate-risk prostate cancer using machine learning.International urology and nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to demonstrate the performance of machine learning algorithms to distinguish clinically significant prostate cancer (csPCa) from clinically insignificant prostate cancer (ciPCa) in prostate bi-parametric magnetic resonance imaging (MRI) using radiomics features.
methodsMRI images of patients who were diagnosed with cancer with histopathological confirmation following prostate MRI were collected retrospectively. Patients with a Gleason score of 3+3 were considered to have clinically ciPCa, and patients with a Gleason score of 3+4 and above were considered to have csPCa. Radiomics features were extracted from T2-weighted (T2W) images, apparent diffusion coefficient (ADC) images, and their corresponding Laplacian of Gaussian (LoG) filtered versions. Additionally, a third feature subset was created by combining the T2W and ADC images, enhancing the analysis with an integrated approach. Once the features were extracted, Pearson’s correlation coefficient and selection were performed using wrapper-based sequential algorithms. The models were then built using support vector machine (SVM) and logistic regression (LR) machine learning algorithms. The models were validated using a five-fold cross-validation technique.
resultsThis study included 77 patients, 30 with ciPCA and 47 with csPCA. From each image, four images were extracted with LoG filtering, and 111 features were obtained from each image. After feature selection, 5 features were obtained from T2W images, 5 from ADC images, and 15 from the combined dataset. In the SVM model, area under the curve (AUC) values of 0.64 for T2W, 0.86 for ADC, and 0.86 for the combined dataset were obtained in the test set. In the LR model, AUC values of 0.79 for T2W, 0.86 for ADC, and 0.85 for the combined dataset were obtained.
conclusionMachine learning models developed with radiomics can provide a decision support system to complement pathology results and help avoid invasive procedures such as re-biopsies or follow-up biopsies that are sometimes necessary today. CLINICAL SIGNIFICANCE: This study demonstrates that machine learning models using radiomics features derived from bi-parametric MRI can discriminate csPCa from clinically insignificant PCa. These findings suggest that radiomics-based machine learning models have the potential to reduce the need for re-biopsy in cases of indeterminate pathology, assist in diagnosing pathology–radiology discordance, and support treatment decision-making in the management of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.